{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:39:03Z","timestamp":1786117143515,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100008903","name":"ministry of health and welfare","doi-asserted-by":"publisher","award":["RS-2025-25459471"],"award-info":[{"award-number":["RS-2025-25459471"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["IRIS RS-2025-00521527"],"award-info":[{"award-number":["IRIS RS-2025-00521527"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tepotinib received Food and Drug Administration approval for advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation (METex14m) based on a single-arm trial. However, the comparative effectiveness between tepotinib and standard of care (SoC) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aim to assess the long-term comparative effectiveness between first-line tepotinib and SoC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This retrospective comparative effectiveness study was conducted based on a matching-adjusted indirect comparison using aggregate data for Asian patients of the VISION trial for the tepotinib arm, and data of patients with METex14m who received SoC from Samsung Medical Center data in January 2008 and February 2024 for the SoC arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Hazard ratio (HR) and its confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were assessed through a Cox proportional hazards model. A partitioned survival model was run for a lifetime using four different scenarios to estimate long-term quality-adjusted life-years (QALYs), which reflect patients\u2019 health-related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the SoC arm (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944), 26 and 18 were treated with an immunotherapy-containing regimen and chemotherapy, as their first-line SoC. Thirty (68.2%) of the SoC (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944) arm received subsequent METex14-targeting therapy. Tepotinib significantly improved PFS compared to SoC (HR (95% CI), 0.38 (0.22\u20130.63)). The PFS improvement was more pronounced when compared to the chemotherapy subgroup (HR (95% CI), 0.20 (0.10\u20130.38)) and was also evident in the immunotherapy-containing regimen subgroup (HR (95% CI), 0.55 (0.29\u20131.03)). Although OS did not differ significantly (HR (95% CI), 1.04 (0.56\u20131.93)), the partitioned survival model yielded an additional 0.2409\u20130.3039 QALYs in the tepotinib arm, showing HRQoL benefits of tepotinib over SoC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The significant PFS benefit of first-line tepotinib over SoC extended to long-term HRQoL gains, indicating tepotinib is considered one of the first-line treatment options. Future studies based on multicenter data or head-to-head trials would be able to verify the efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261469538","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:32:50Z","timestamp":1785825170000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-240X","authenticated-orcid":false,"given":"Joo-Young","family":"Byun","sequence":"first","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA"},{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2013Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7754","authenticated-orcid":false,"given":"Eui-Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro Jangan-gu, Suwon-si, Gyeonggi-do, Suwon 16419, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1962"},{"key":"e_1_3_4_4_2","unstructured":"U.S. Food & Drug Administration. FDA approves tepotinib for metastatic non-small cell lung cancer https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer (2024 accessed 12 September 2024)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01038-z"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02615-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-531"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1416"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1511"},{"key":"e_1_3_4_14_2","volume-title":"Nice DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching","author":"Latimer NR","year":"2014","unstructured":"Latimer NR, Abrams KR. Nice DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. London: National Institute for Health and Care Excellence (NICE), 2014."},{"key":"e_1_3_4_15_2","author":"Statistics Korea","year":"2022","unstructured":"Statistics Korea. Life table (2022), Statistics Korea, 2022.","journal-title":"Life table (2022)"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20170"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0527-z"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1521416"},{"key":"e_1_3_4_19_2","unstructured":"Health Insurance Review and Assessment Service. Drug Economic Evaluation Guideline 2021."},{"key":"e_1_3_4_20_2","unstructured":"Latimer N. NICE DSU Technical support document 14: survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data Report by the Decision Support Unit 2011."},{"key":"e_1_3_4_21_2","unstructured":"Rutherford M Lambert P Sweeting M et al. NICE DSU technical support document 21: flexible methods for survival analysis Report by the Decision Support Unit 2020."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.173"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2414"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13780"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_3_4_26_2","first-page":"147","article-title":"A concise review of the approved MET TKIs (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) in China for MET exon 14 splice site mutated (METex14+) NSCLC circa 2025","volume":"16","author":"Hu Y","year":"2025","unstructured":"Hu Y, Ou S-HI. A concise review of the approved MET TKIs (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) in China for MET exon 14 splice site mutated (METex14+) NSCLC circa 2025. Lung Cancer (Auckl) 2025; 16: 147\u2013159.","journal-title":"Lung Cancer (Auckl)"},{"key":"e_1_3_4_27_2","first-page":"101834","article-title":"Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory phase 3b study","volume":"69","author":"Yu Y","year":"2026","unstructured":"Yu Y, Guo Q, Zhang Y, et al. Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory phase 3b study. Lancet Reg Health West Pac 2026; 69: 101834.","journal-title":"Lancet Reg Health West Pac"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101952"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02363"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-638"},{"key":"e_1_3_4_31_2","volume-title":"Tepotinib for treating advanced non-small cell lung cancer with MET gene alterations","author":"National Institute for Health and Care Excellence","year":"2022","unstructured":"National Institute for Health and Care Excellence. Final Appraisal Document. Tepotinib for treating advanced non-small cell lung cancer with MET gene alterations. London: National Institute for Health and Care Excellence (NICE), 2022."},{"key":"e_1_3_4_32_2","author":"CADTH Reimbursement Review","year":"2022","unstructured":"CADTH Reimbursement Review. Tepotinib (Tepmetko), 2022.","journal-title":"Tepotinib (Tepmetko)"},{"key":"e_1_3_4_33_2","unstructured":"The Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines. 3A.4 Model transition probabilities or variables transformation and extrapolation https:\/\/pbac.pbs.gov.au\/section-3a\/3a-4-model-transition-probabilities-or-variables-transformation-extrapolation.html (2016 accessed 12 September 2024)."},{"key":"e_1_3_4_34_2","volume-title":"Adoption of piecewise modelling: a review of NICE health technology appraisals in oncology","author":"Liu B","year":"2022","unstructured":"Liu B, Griffiths M. Adoption of piecewise modelling: a review of NICE health technology appraisals in oncology. Paper presented at ISPOR, Washington, DC, USA, 2022."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03352-5"},{"key":"e_1_3_4_36_2","article-title":"Chinese version of the EQ-5D preference weights: applicability in a Chinese general population","volume":"11","author":"Wu C","year":"2016","unstructured":"Wu C, Gong Y, Wu J, et al. Chinese version of the EQ-5D preference weights: applicability in a Chinese general population. PLoS One 2016; 11: e0164334.","journal-title":"PLoS One"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003862"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261469538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261469538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261469538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:19:00Z","timestamp":1786022340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261469538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["10.1177\/17588359261469538"],"URL":"https:\/\/doi.org\/10.1177\/17588359261469538","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261469538"}}